1950s was the golden age of antibiotics development.
However, overuse and misuse of antibiotics caused the dramatic increase of bacterial resistance to antibiotics, and at the same time, the antibiotics development market decreased dramatically. Most of newly marketed drugs for the past 30 years were only modified products from conventional existing antibiotics, and the ones being currently used are also derived from the products which were developed between 1900 and 1984.
High development cost along with long and complicated regulations compared to low market perspective and small return profit was the inhibition factor of antibiotics development market. So, most pharmaceutical companies had been focusing on chemical modification only to detour bacterial resistance mechanism, starting from existing antibiotics.
World Health Organization (WHO) defines current time as Post-Antibiotics Era and Centers for Diseases Control of USA reported that, due to serious antibiotic-resistant bacterial infections, more than 2 millions people are suffering yearly and these infections cause 23,000 death a year.
Worldwide realization about this tendency induced governments and private sectors to make multilateral efforts to minimize overuse and misuse of antibiotics, but it seems not sufficient to stop bacterial multiple drug resistance which has been rapidly spreading across bacterial species barriers.
With time, currently used antibiotics will become more and more ineffective…bigger and bigger. Especially, dealing with Gram Negative Bacteria having distinct cell wall structure and diverse resistance mechanisms, which hinders antibiotics penetration into cell, is very urgent task.
The most important point in developing next generation antibiotic material against Gram-Negative Bacteria is to discover a differentiated mode of action and to develop such highly innovative mechanism as commercialized novel product.
In order to surpass scientific barrier of totally new application and complicated regulations, development of Gram-Negative Bacterial antibiotics demands high level of cooperation among academia, industry and government, added to extensive research on the subject. With core discoveries being shared and companies’ industrial expertise joined, development of long-running and profitable novel antibiotic material will be possible, even in the Post-Antibiotics Era.
iNtRON Biotechnology has established N-Rephasin, the original technology of bacteria controlling system using Endolysin and bacteriophages. And based on this technology, iNtRON is developing a novel conceptual antibiotic treatment targeting Gram Negative Bacteria. We will bring a groundbreaking technology to the world in order to tackle resistant bacteria problem that humankind faces in the upcoming Post-Antibacterial Era.
it is iNtRON.
*Ref: Scientific Roadmap for Antibiotics Discovery-Pew Chartable Report, 2016